Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Phase 2 Completed 75 enrolled National Institute of Allergy and Infectious Diseases (NIAID) ViiV Healthcare · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the safety, tolerability, antiviral activity, and pharmacokinetics of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.

Timeline

Start: 2019-12-31
Primary completion: 2024-04-29
Completion: 2024-04-29

Publications

Kuritzkes DR. Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV. Curr Opin HIV AIDS. 2023 Jul 1;18(4):225-228. doi: 10.1097/COH.0000000000000801. Epub 2023 May 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cabotegravir	Small molecule	30 mg	Oral
Subject	Cabotegravir	Small molecule	400 mg	Oral
Subject	VRC07-523LS	Monoclonal antibody	40 mg/kg	Intravenous

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

Summary

Timeline

Publications

Drugs

Indications